MDT-AP-1128
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 22.32
- os_event
- false
- age_years
- 3
- sex
- M
- new_clusters
- C4
- umap1_2d
- 4.447851682
- umap2_2d
- 3.679990022
- umap1_3d
- 1.138204398
- umap2_3d
- -1.558992105
- umap3_3d
- -2.75350973
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.560
- ANGIOGENESIS+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- TNFA_SIGNALING_VIA_NFKB+0.520
- INTERFERON_ALPHA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.490
- INTERFERON_GAMMA_RESPONSE+0.490
- INFLAMMATORY_RESPONSE+0.480
- COAGULATION+0.450
- IL2_STAT5_SIGNALING+0.440
Top 10 suppressed
- MYC_TARGETS_V1-0.540
- OXIDATIVE_PHOSPHORYLATION-0.450
- PROTEIN_SECRETION-0.360
- E2F_TARGETS-0.340
- MYC_TARGETS_V2-0.340
- MTORC1_SIGNALING-0.300
- PEROXISOME-0.270
- DNA_REPAIR-0.260
- FATTY_ACID_METABOLISM-0.220
- G2M_CHECKPOINT-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TA9WP4TH | Med | Medulloblastoma | 0.939 |
| 2 | BS_Z28VKGNS | Neurofibroma | — | 0.934 |
| 3 | BS_TQ5QHR17 | Neurofibroma | — | 0.928 |
| 4 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.923 |
| 5 | X17a4d870.71ef.4580.91db.071219517f26 | — | cohortSQ1 | 0.922 |
| 6 | BS_0RF0EZTV | Neurofibroma | — | 0.917 |
| 7 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.915 |
| 8 | BS_TAHV8N04 | Neurofibroma | — | 0.915 |
| 9 | X25d3a106.8a9a.4285.9b02.1ba01b7a9ad2 | — | cohortMD2 | 0.914 |
| 10 | MDT-AP-1168 | Med | Medulloblastoma | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.440 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.410 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.400 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.390 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APOPTOSIS | 0.340 | Idelalisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |